24th Nov 2015 09:22
LONDON (Alliance News) - Pharmaceutical services company Clinigen Group PLC on Tuesday said its clinical trial services business has secured a two-year renewal on its European clinical trial distribution deal with Accord Healthcare, a marketing subsidiary of India's Intas Pharmaceuticals.
The agreement has been extended to include four new products, along with drugs from additional therapeutic areas such as diabetes and transplant rejection.
No financial details on the renewal were disclosed.
"Clinigen is committed to providing the best possible clinical trial service and distribution capabilities. This has been demonstrated by both the continuation of this strong partnership and Accord's decision to extend the agreement to include four more key products. We are pleased to be working with the Accord team for another two years," said Steve Glass, Clinigen's managing director.
Shares in Clinigen were down 1.1% to 633.00 pence on Tuesday morning.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L